Straits Times Index
3,215.40 +10.58 (+0.33%) S&P 500
4,320.06 -9.94 (-0.23%) Dow
33,963.84 -106.56 (-0.31%) Nasdaq
13,211.81 -12.19 (-0.09%) Bitcoin USD
26,047.42 -544.08 (-2.05%) CMC Crypto 200
556.76 -11.28 (-1.99%)
GILD Jan 2024 90.000 call
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 90.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.07k |
Motley Fool3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
ZacksGilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Business WireCHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
FOSTER CITY, Calif., September 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can
